CALIDI BIOTHERAPEUTICS INC (CLDI) Stock Price, Quote, News and Overview
NYSEARCA:CLDI - NYSE Arca - US3207033099 - Common Stock - Currency: USD
CLDI Quote, Performance and Key Statistics
0.4825
0 (0%)
The current stock price of CLDI is 0.4825 USD. In the past month the price decreased by -16.95%. In the past year, price decreased by -75.51%.
CLDI Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.83 | 342.01B | ||
| AMGN | AMGEN INC | 14.32 | 152.57B | ||
| GILD | GILEAD SCIENCES INC | 13.34 | 128.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1720.21 | 128.25B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.32 | 64.50B | ||
| ARGX | ARGENX SE - ADR | 336.79 | 39.07B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.19B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.55B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.62B | ||
| NTRA | NATERA INC | N/A | 20.46B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.19B | ||
| BIIB | BIOGEN INC | 7.34 | 17.70B |
Related stock screener links
About CLDI
Company Profile
Calidi Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which engages in stem cell-based platforms to revolutionize oncolytic virotherapies. The company is headquartered in San Diego, California and currently employs 28 full-time employees. The company went IPO on 2021-09-10. The firm is developing proprietary allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses (vaccinia virus and adenovirus) and, potentially, other molecules to cancer patients. The company is focused on developing two proprietary stem cell-based platforms and one enveloped vaccinia virus platform designed to protect the oncolytic virus, whether natural or engineered, from neutralization by the patient’s immune defenses, allowing for greater infection of the tumor cells and leading to a potential improvement in the antitumor activity of oncolytic viruses over traditional naked oncolytic virus therapies. Its product candidates include the CLD-101 product for high grade glioma (HGG), CLD-101 product for Recurrent HGG, CLD-201 product for solid tumors, CLD-301 (AAA) for multiple indications and CLD-400 (RTNova) for certain lung cancer and metastatic solid tumors.
Company Info
CALIDI BIOTHERAPEUTICS INC
4475 Executive Drive, Suite 200
San Diego CALIFORNIA US
Employees: 41
Company Website: https://www.calidibio.com/
Investor Relations: http://calidibio.com/investors/
Phone: 18587949600
CALIDI BIOTHERAPEUTICS INC / CLDI FAQ
What is the stock price of CALIDI BIOTHERAPEUTICS INC today?
The current stock price of CLDI is 0.4825 USD.
What is the ticker symbol for CALIDI BIOTHERAPEUTICS INC stock?
The exchange symbol of CALIDI BIOTHERAPEUTICS INC is CLDI and it is listed on the NYSE Arca exchange.
On which exchange is CLDI stock listed?
CLDI stock is listed on the NYSE Arca exchange.
What is the price forecast or stock price prediction for CALIDI BIOTHERAPEUTICS INC stock?
8 analysts have analysed CLDI and the average price target is 6.38 USD. This implies a price increase of 1221.24% is expected in the next year compared to the current price of 0.4825. Check the CALIDI BIOTHERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CALIDI BIOTHERAPEUTICS INC worth?
CALIDI BIOTHERAPEUTICS INC (CLDI) has a market capitalization of 16.66M USD. This makes CLDI a Nano Cap stock.
How many employees does CALIDI BIOTHERAPEUTICS INC have?
CALIDI BIOTHERAPEUTICS INC (CLDI) currently has 41 employees.
What are the support and resistance levels for CALIDI BIOTHERAPEUTICS INC (CLDI) stock?
CALIDI BIOTHERAPEUTICS INC (CLDI) has a support level at 0.47 and a resistance level at 0.5. Check the full technical report for a detailed analysis of CLDI support and resistance levels.
Should I buy CALIDI BIOTHERAPEUTICS INC (CLDI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CLDI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CLDI, evaluating the profitability, health, valuation and growth aspects
- CALIDI BIOTHERAPEUTICS INC (CLDI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CALIDI BIOTHERAPEUTICS INC (CLDI) Sales and EPS estimates to see what analysts future expectations are.
- CALIDI BIOTHERAPEUTICS INC (CLDI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CALIDI BIOTHERAPEUTICS INC (CLDI) Insider and Institutional Ownership to learn about the owners and their transactions.
- CALIDI BIOTHERAPEUTICS INC (CLDI) Stock Chart to make your own analysis
- CALIDI BIOTHERAPEUTICS INC (CLDI) Latest news and press-releases to stay up to date.
Does CALIDI BIOTHERAPEUTICS INC (CLDI) stock pay dividends?
CLDI does not pay a dividend.
When does CALIDI BIOTHERAPEUTICS INC (CLDI) report earnings?
CALIDI BIOTHERAPEUTICS INC (CLDI) will report earnings on 2025-05-20.
What is the Price/Earnings (PE) ratio of CALIDI BIOTHERAPEUTICS INC (CLDI)?
CALIDI BIOTHERAPEUTICS INC (CLDI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.56).
What is the Short Interest ratio of CALIDI BIOTHERAPEUTICS INC (CLDI) stock?
The outstanding short interest for CALIDI BIOTHERAPEUTICS INC (CLDI) is 0.53% of its float. Check the ownership tab for more information on the CLDI short interest.
CLDI Technical Analysis
CLDI Financial Highlights
Over the last trailing twelve months CLDI reported a non-GAAP Earnings per Share(EPS) of -4.56.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -387.44% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CLDI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 88% to CLDI. The Buy consensus is the average rating of analysts ratings from 8 analysts.